Joint (NASDAQ:JYNT) Announces Earnings Results

Joint (NASDAQ:JYNT) issued its earnings results on Thursday. The company reported $0.05 earnings per share for the quarter, hitting the consensus estimate of $0.05, FiscalAI reports. Joint had a return on equity of 11.70% and a net margin of 6.49%.The company had revenue of $15.18 million for the quarter, compared to analyst estimates of $14.57 million.

Here are the key takeaways from Joint’s conference call:

• Profitability and cash flow improved sharply: Q2 revenue rose 14% to $15.2 million, Adjusted EBITDA from continuing operations increased to $1.5 million from $88,000, and free cash flow grew $1.6 million to $1.9 million.
• Refranchising is nearing completion, with clinic ownership transfers and management service agreements progressing across the three sale bundles. Once finalized, The Joint expects to have only three remaining company-owned or managed clinics, supporting a more capital-light model.
• Patient retention reached its best level in more than five years following the rollout of flexible membership options, while active-member trends improved sequentially. Management also reported no meaningful patient pushback to price increases implemented at more than 500 clinics.
• System-wide sales declined 3.7% year over year and Q2 comparable sales were negative 2.8%, although management said July and second-half trends were improving.
• The company reduced its 2026 new-clinic opening outlook to 22–26 from 30–35, and expects year-end clinic count to be below 2025 levels as closures and portfolio optimization offset new openings. Full-year guidance was otherwise reiterated, including $12.5 million–$13.5 million of consolidated Adjusted EBITDA.

Joint Price Performance

Shares of NASDAQ JYNT traded up $0.11 during trading hours on Friday, hitting $8.33. 104,765 shares of the company’s stock were exchanged, compared to its average volume of 60,308. The company’s 50-day moving average price is $8.76 and its 200-day moving average price is $8.87. Joint has a 1-year low of $7.50 and a 1-year high of $11.26. The stock has a market capitalization of $118.79 million, a price-to-earnings ratio of 30.85 and a beta of 1.10.

Analyst Ratings Changes

JYNT has been the subject of several recent research reports. Wall Street Zen raised Joint from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Weiss Ratings raised shares of Joint from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, June 12th. Finally, Zacks Research cut shares of Joint from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

Insider Transactions at Joint

In other Joint news, major shareholder Charles E. Jobson purchased 127,676 shares of the company’s stock in a transaction on Tuesday, May 12th. The shares were bought at an average cost of $8.57 per share, with a total value of $1,094,183.32. Following the transaction, the insider directly owned 1,773,479 shares in the company, valued at approximately $15,198,715.03. This represents a 7.76% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 30.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Joint

Several hedge funds and other institutional investors have recently modified their holdings of JYNT. Deutsche Bank AG grew its holdings in Joint by 1.8% during the fourth quarter. Deutsche Bank AG now owns 84,745 shares of the company’s stock worth $739,000 after purchasing an additional 1,462 shares during the period. BNP Paribas Financial Markets lifted its position in shares of Joint by 104.7% in the third quarter. BNP Paribas Financial Markets now owns 2,935 shares of the company’s stock valued at $28,000 after buying an additional 1,501 shares during the last quarter. Barclays PLC boosted its stake in shares of Joint by 5.3% during the 4th quarter. Barclays PLC now owns 32,235 shares of the company’s stock worth $281,000 after acquiring an additional 1,623 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Joint by 25.9% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 8,244 shares of the company’s stock worth $95,000 after acquiring an additional 1,698 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of Joint by 32.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,412 shares of the company’s stock worth $86,000 after acquiring an additional 1,810 shares during the last quarter. Institutional investors and hedge funds own 76.88% of the company’s stock.

About Joint

The Joint Chiropractic, Inc, doing business as Joint (NASDAQ: JYNT), is a franchisor and operator of outpatient chiropractic clinics in the United States. Under its flagship The Joint Chiropractic brand, the company offers membership-based, cash-focused spinal adjustment services designed to promote accessible, routine care for neck and back discomfort. By removing insurance requirements and offering walk-in visits, Joint aims to streamline the patient experience and reduce cost barriers to ongoing chiropractic treatment.

Joint’s growth strategy centers on partnering with franchisees to expand its network of clinics.